From pomegranate to cell cleaner: What is Urolithin A?
It starts with a pomegranate, more precisely with the polyphenols in its peel, called ellagitannins. When we drink pomegranate juice or eat walnuts, raspberries, or strawberries, these plant compounds reach the large intestine. There, a highly specialized community of gut bacteria awaits that can convert ellagitannins into a substance that has become the focus of intensive aging research in recent years: Urolithin A.
What makes this compound remarkable is not its origin but its effect. Urolithin A activates a cellular cleaning process called mitophagy, the targeted breakdown and replacement of damaged mitochondria. Mitochondria are the powerhouses of our cells. With age, damage to their DNA accumulates. Damaged mitochondria work inefficiently, produce less energy, and release more harmful oxygen radicals. [1]
Since 2016, research on Urolithin A has gained significant momentum. In 2024 alone, over 125 scientific papers on this substance were published. There are now four placebo-controlled human studies available, which is unusually many for a longevity substance.
The microbiome decides who benefits
The first hurdle is in the gut. Not everyone can naturally produce Urolithin A. A study with 100 healthy adults showed that only about 40% of participants produced significant amounts of Urolithin A in their blood after drinking pomegranate juice. [2]
The cause lies in the individual composition of the gut microbiome. Researchers distinguish three so-called urolithin metabotypes: UM-A (efficient producers), UM-B (low production), and UM-0 (no production). Which type a person belongs to depends on certain bacterial strains and can only be influenced to a limited extent by diet. [3]
Direct supplementation bypasses this problem. A single dose of 500 mg led to plasma levels six times higher than after pomegranate juice, regardless of metabotype. [2]
How Urolithin A renews mitochondria
Urolithin A activates the PINK1/Parkin pathway, a central signaling pathway of mitophagy. In this process, damaged mitochondria are recognized by the cell machinery, enclosed in autophagosomes, and degraded. New, functional mitochondria are formed from the breakdown materials. This process declines with age, affecting muscle strength, immune function, and cognitive performance.
This mechanism is closely related to general autophagy, which is also activated by spermidine. Urolithin A specifically targets mitochondria, while spermidine triggers the broader cellular recycling process. Basic research began in 2016 with a Nature Medicine publication from ETH Lausanne. [4]
What clinical studies show and what they do not
So far, four placebo-controlled human studies are available. This is a solid foundation for a longevity substance but with important limitations that must be honestly considered when evaluating.
The first was by Andreux et al. 2019 in Nature Metabolism: 60 healthy, inactive older adults received Urolithin A for four weeks. The result was proof-of-concept: safe, well tolerated, and measurable improvements in mitochondrial biomarkers. The first evidence that the mechanism also activates in the human body. [5]
The most extensive efficacy study to date was published by Singh et al. 2022 in Cell Reports Medicine. Eighty-eight overweight, inactive adults aged 45 to 65 received 500 or 1,000 mg of Urolithin A daily for four months. The results showed a significant improvement in leg muscle strength by about 12% and a reduction in the inflammation marker CRP. Important to know: the primary endpoint, peak power output, was not significantly improved. The positive strength and endurance findings were secondary endpoints. [6]
A second study from the same year, Liu et al. in JAMA Network Open, examined an older population: 66 adults aged 65 to 90 received 1,000 mg daily for four months. Significant improvements in muscle endurance were seen after just two months, and acylcarnitines as well as CRP decreased measurably. Here too, the study missed its primary endpoint: the 6-minute walk test and ATP production in hand muscles did not improve significantly compared to placebo. [7]
Both studies show a consistent pattern: muscle endurance and inflammation markers reliably improve, while the primary performance endpoints improve only partially. This is an honest picture, not a failure, but also not an unqualified success.
The MitoImmune study by Denk et al., 2025, published in Nature Aging, expanded the view on the immune system. Fifty healthy adults aged 45 to 70 received 1,000 mg of Urolithin A daily for 28 days. The fatty acid oxidation capacity of CD8+ T cells increased significantly (+14.7 percentage points, p=0.006), and mitochondrial biogenesis in immune cells increased. [8] These results suggest that Urolithin A could support not only muscle cells but also immune cells in maintaining their mitochondrial function with age.
Additionally, a smaller study by Zhao et al. 2024 in the Journal of the International Society of Sports Nutrition examined 20 trained male athletes over eight weeks. Muscle strength, endurance, and exercise-induced inflammatory markers improved significantly. [9] The sample is very small and exclusively male, limiting generalizability, but the finding shows that Urolithin A can also work in already trained individuals.
Hope for brain health: no human data yet
Urolithin A can cross the blood-brain barrier. [10] In three Alzheimer’s mouse models, long-term treatment improved learning and memory performance, and reduced amyloid-beta and tau pathologies. [11] Clinical studies in humans are still pending. A currently ongoing study with about 650 participants aims to systematically investigate the effect on brain health in humans for the first time. Until those results are available, the animal and mechanistic data are biologically plausible but not proof of effect in humans.
Safety profile and dosage
A 2024 systematic review with over 250 participants confirmed the favorable safety profile. [12] Urolithin A is not genotoxic. [13] GRAS status in the USA, Novel Food approval in the EU. Long-term data beyond four months are missing. This does not mean the substance is unsafe, but that the research is still young.
Dosage according to current studies: 500–1,000 mg daily, taken in the morning with a meal.
Current state of evidence
The evidence base is comparatively robust for a longevity substance. Four RCTs in humans are available, two of which missed their primary endpoint. Sample sizes remain small (20–88 participants), and long-term data are lacking.
| Level of evidence | Study type | Finding | Assessment |
|---|---|---|---|
| Human studies | RCT (n=88, 45–65 years) | Muscle strength +12%, endurance ↑, CRP ↓ after 4 months. Primary endpoint (Peak Power Output) not significant. (Singh et al. 2022, Cell Rep Med) | 🟢 Strong, largest UA efficacy study |
| Human studies | RCT (n=66, 65–90 years) | Significant improvement in muscle endurance (hand + leg) after 2 months. Primary endpoint (6MWT, ATP) not significant. (Liu et al. 2022, JAMA Netw Open) | 🟢 Strong, primary endpoint missed |
| Human studies | RCT (n=50, 45–70 years) | CD8+ T cell function increased, FAO capacity +14.7 percentage points, mitochondrial biogenesis increased (Denk et al. 2025, Nat Aging) | 🟢 Strong, immunological effects proven |
| Human studies | RCT (n=66, 65+ years) | First safety and efficacy study in humans, mitochondrial biomarkers increased (Andreux et al. 2019, Nat Metab) | 🟢 Strong, proof-of-concept |
| Human studies | RCT (n=20, athletes) | Increased muscle strength and endurance in trained men after 8 weeks (Zhao et al. 2024, JISSN) | 🟡 Moderate, small sample, only men |
| Animal model | Mouse study | Mitophagy activation, extended lifespan in C. elegans; increased muscle function in aging mice (Ryu et al. 2016, Nat Med) | 🟡 Limited, transferability to humans unclear |
| Mechanistic | In vitro / cell culture | Mitophagy activation via PINK1/Parkin pathway in mammalian cells; blood-brain barrier crossing demonstrated | 🔵 Basis, explains mechanism |
| Gaps | Missing data | No long-term studies >4 months. No human studies on brain health. No direct longevity proof. Two RCTs missed their primary endpoint. | 🔴 Open, to be considered critically |
🟢 Strong evidence (RCT in humans) · 🟡 Moderate evidence · 🔵 Mechanistic evidence · 🔴 Missing data / limitations
Who is Urolithin A suitable for?
Based on current evidence, the substance is especially relevant for people over 40, whose mitochondrial function declines with age. Additionally, about 60% of the population cannot efficiently produce Urolithin A from food. This group particularly benefits from direct supplementation. Active people and athletes who want to specifically support muscle regeneration and endurance capacity also find concrete indications in the data.
Urolithin A differs mechanistically from NMN (NAD+ increase) and spermidine (general autophagy). The three approaches address different levels of cellular health and can be combined.
What does this mean in practice?
Urolithin A is not a miracle pill. It is a substance whose mechanism of action is well understood and for which clinical data in humans exist. This is by no means a given for a longevity substance. The findings on muscle endurance and inflammation markers are consistent. Two studies missed their primary endpoint, which should be considered in personal assessment.
Anyone taking Urolithin A should pay attention to lab-tested purity and clearly declared dosage. Since the substance is classified as a Novel Food in the EU, only approved products may be marketed.
